329 filings
Page 2 of 17
8-K
rf4ytqln4965bz7jitl
7 Dec 21
Submission of Matters to a Vote of Security Holders
8:00am
8-K
pw3bqd
3 Dec 21
Regulation FD Disclosure
12:00pm
8-K
3m7ky2ovss6 wa
15 Nov 21
Board approves exploration of a Company-sponsored belapectin oncology program complementing our ongoing NASH cirrhosis program
7:55am
8-K
x1tsm
21 Sep 21
Galectin Therapeutics Announces $20 Million Convertible Debt Financing from Its Chairman, Richard E. Uihlein
7:56am
8-K
8r85888l
13 Sep 21
Regulation FD Disclosure
7:00am
8-K
6uodptd
16 Aug 21
Results of Operations and Financial Condition
9:01am
8-K
ifmuod0x33gqupmljs6
26 Jul 21
Regulation FD Disclosure
9:27am
8-K
dugcbu v3ghv
9 Jul 21
Other Events
7:59am
8-K
kcbuat t979s60zdtxo4
17 May 21
Continued Favorable Developments in both NAVIGATE and Cancer Combination Immunotherapy Trials
7:56am
8-K
d4jln2sc2mg k9k
19 Apr 21
Entry into a Material Definitive Agreement
7:51am
8-K
pq2trbggx648 lp
31 Mar 21
Galectin Therapeutics Reports Fiscal 2020 Financial Results
7:53am
8-K
a8fk8g8dvwvarlmgs3
9 Mar 21
Regulation FD Disclosure
7:01am
8-K
326k r30g
7 Dec 20
Submission of Matters to a Vote of Security Holders
4:00pm
8-K
xikfgrr
3 Dec 20
Regulation FD Disclosure
12:31pm
8-K
9c0b5n4c07upnkq0o
9 Nov 20
Galectin Therapeutics Provides Business Update
7:47am
8-K
kmskomco30mvbahah
29 Sep 20
Regulation FD Disclosure
3:55pm
8-K
9q9k85951ew8gep7k7o
22 Sep 20
Presentation to discuss the details of the newly launched Phase 2b/3 NASH-RX clinical trial; Introduce new CEO and President Joel Lewis
7:50am
8-K
85xl 8cucm5jz
2 Sep 20
Galectin Therapeutics Appoints Joel Lewis as Chief Executive Officer
7:51am
8-K
z2fbthp4upthbgem
10 Aug 20
NASH-RX Trial Continues to Enroll New Patients
7:55am
8-K
y7u7 gdp9
30 Jun 20
Galectin Therapeutics Announces Commencement of patient enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis
7:58am